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The OARSI histopathology initiative – the tasks and limitationsIn order to increase our knowledge on the pathogenesis and
treatment of osteoarthritis (OA), experimental in vivo studies have
ﬂourished over the past decade in the literature. They have been
performed in many species, using many different scoring systems.
An absence of consensus in the scientiﬁc community about the
scoring systems to be used according to each species has introduced
confusion and sometimes discrepancies between studies.
The standardization of scoring systems to evaluate the OA
disease process is a topic of obvious importance for the OA scientiﬁc
community, both in academic as well as industrial research. This
will permit comparison of results coming from different studies.
Osteoarthritis Research Society International (OARSI) started about
a decade ago its ﬁrst histopathology initiative lead by Ken Pritzker
et al.1 which resulted in the development of the Pritzker-score
published in 2006. The task of the follow-up histopathology
initiative was to achieve a consensus of scoring systems for the
most important species used in OA animal model research.
Thus, the core task of the present (second) histopathology
initiative coordinated by Tom Aigner was to propose species-
speciﬁc consensus scoring systems which should be reasonably
easy to handle and should be used by the community at least in
parallel (in order to assure comparability of results).
The suggested scoring criteria at this stage cannot be considered
as to be perfect although the best experts in the ﬁeld were involved
in this initiative: instead, the community should use it and a follow-
up within 5 years is envisaged. This work is part of an area which is
on the way to develop and improve. So it is in part a starting
attempt and not a ﬁnal consensus. All scoring systems proposed
will require further validation.1063-4584/$ – see front matter  2010 Osteoarthritis Research Society International. Pu
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